TABLE 1.
Epidemiological and virological data
| Patienta | Age/sex/citya | Sample/dateb | CD4 count (cells/μl) | p24 Ag (pg/ml)c | Treatment |
|---|---|---|---|---|---|
| ESP1 | 35/M/Madrid | 0/Sept. ’95 | 290 | 15 | Noned |
| +4/Jan. ’96 | 182 | 21 | None | ||
| +11/Aug. ’96 | 152 | 34 | None | ||
| +19/Apr. ’97 | 144 | 25 | None | ||
| ESP2 | 34/F/Madrid | +4/Jan. ’96 | 48 | 390 | None |
| +11/Aug. ’96 | 24 | 131 | AZT + ddIe | ||
| +17/Feb. ’97 | 165 | 50 | d4T + 3TC + IDVf | ||
| ESP3 | 45/M/Madrid | ESP3/Jan. ’97 | 96 | 105 | None |
| ESP4 | 15/M/Barcelona | ESP4/Feb. ’97 | 16 | 0 | AZT + 3TC |
a
Age is given in years. Sex: M, male; F, female. City, location where the sample was collected.
b
The number following the patient’s code in the two related isolates (ESP1 and ESP2) indicates months after the first HIV-1 group O isolate described (ESP1/0) (50) at the time of sampling of lymphocytes. Samples ESP3 and ESP4 are unique.
c
p24 antigen (Ag) was measured using a commercial kit (HIV-1 p24 Antigen Assay; Coulter, Miami, Fla.).
d
No treatment with antiretroviral inhibitors.
e
Patient received AZT + ddI therapy from June to September 1996.
f
Patient received d4T + 3TC + indinavir (IDV) from September 1996 to the present.